IRAK4 Degrader GS-6791 Inhibits TLR And IL-1R-Driven Inflammatory Signaling, And Ameliorates Disease In A Preclinical Arthritis Model By aterrado@waterhousebrands.com / January 7, 2025
Small Molecule Inhibition Of The Ubiquitin Ligase CBL-B With NX-1607 Results In Potent T And NK Cell Mediated Anti-Tumor Response By aterrado@waterhousebrands.com / January 7, 2025
Initial Clinical Characterization Of Novel Proximal Biomarkers For NX-1607, A First-In-Class Oral CBL-B Inhibitor, In Patients With Advanced Malignancies By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of The CBL-B E3 Ubiquitin Ligase, Promotes T And NK Cell Activation And Enhances NK-Mediated ADCC In A Mouse Lymphoma Tumor Model By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of CBL-B, Is Efficacious As A Single Agent And In Combination With Rituximab In Preclinical Mouse Models Of Lymphoma By aterrado@waterhousebrands.com / January 7, 2025
NX-1607, A Small Molecule Inhibitor Of CBL-B, Enhances Anti-PD-1-Mediated Tumor Growth Inhibition By Reshaping Intratumoral Innate And Adaptive Immune Responses By aterrado@waterhousebrands.com / January 7, 2025
NX-5948 Promotes Selective, Sub-Nanomolar Degradation Of Inhibitor-Resistant BTK Mutants By aterrado@waterhousebrands.com / January 7, 2025
NX-5948, A Clinical-Stage BTK Degrader, Achieves Deep Suppression Of BCR, TLR, And Fcr Signaling In Immune Cells And Demonstrates Efficacy In Preclinical Models Of Arthritis And Other Inflammatory Diseases By aterrado@waterhousebrands.com / January 7, 2025
A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies By dev@sirosolutions.com / December 17, 2024
A Rapid Matrix Approach For The Discovery Of Potent IRAK4 Targeted Protein Degraders By dev@sirosolutions.com / December 17, 2024
